Every Form 4 that ProKidney Corp. (PROK) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow PROK and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PROK filings page.
PROKIDNEY CORP. (PROK) director Brian J. G. Pereira reported six sales of Class A Common Stock over August 18–20, 2026, totaling 757,164 shares. Sales included both direct holdings and shares held indirectly by the Brian J. G. Pereira 2012 Irrevocable Trust, at weighted average prices between $1.345 and $1.50 per share in open market or private transactions.
ProKidney Corp. director Brian J.G. Pereira reported exchanging paired Class B common stock and ProKidney Holdings, LLC common units into Class A common stock on August 4, 2026. He converted 81,929 paired securities held directly and 675,235 held through the Brian J. G. Pereira 2012 Irrevocable Trust, receiving equal numbers of Class A shares at a stated price of $0.00 per share. The corresponding Class B and LLC common unit interests for these amounts were reduced to zero.
PROKIDNEY CORP. reported that Chief Technical Officer Kenneth Thomas Locke received an employee stock option grant covering 750,000 shares of Class A Common Stock. The options have an exercise price of $1.8900 per share and expire on July 1, 2036.
The award is compensation-related rather than an open-market purchase. According to the vesting terms, 25% of the option vests on the first anniversary of July 1, 2026, with the remaining 75% vesting in substantially equal monthly installments over the following 36 months, subject to continued employment. Following this grant, Locke holds 750,000 derivative securities directly.
PROKIDNEY CORP. Chief Legal Officer Todd C. Girolamo converted paired interests into common stock. On June 12, 2026, he converted 163,857 Class B Common Stock and an equal number of Common Units in ProKidney Holdings, LLC into 163,857 shares of Class A Common Stock at $0.00 per share.
Following the conversion, he directly holds 327,713 shares of Class A Common Stock. The paired Class B shares and Common Units were originally received in the business combination with ProKidney LP and were exchangeable on a one-for-one basis into Class A shares.
PROKIDNEY CORP. director Alan Lotvin received a grant of stock options as part of non-employee director compensation. The award covers 135,000 options to buy Class A Common Stock at an exercise price of $1.81 per share, all held directly.
The options vest in full on the earlier of the one-year anniversary of the grant date or the company’s next annual general shareholder meeting and expire on May 28, 2036. Following this grant, Lotvin holds 135,000 director stock options linked to the company’s Class A Common Stock.
PROKIDNEY CORP. director Jose Ignacio Jimenez Santos received a grant of 135,000 stock options under the company’s non-employee director compensation policy. The options allow him to buy Class A Common Stock at an exercise price of $1.81 per share and expire on May 28, 2036.
The options will vest in full on the earlier of the one-year anniversary of the grant date or the date of the company’s next annual general shareholder meeting. After this award, he holds 135,000 derivative securities related to Class A Common Stock directly.
PROKIDNEY CORP. director Jennifer A. Fox received a grant of stock options as part of non-employee director compensation. She was awarded 135,000 director stock options, each allowing her to buy one share of Class A Common Stock at an exercise price of $1.81.
The options vest in full on the earlier of one year from the grant date or the company’s next annual general shareholder meeting and expire on May 28, 2036. After this grant, she holds 135,000 options directly, and this is a compensation award rather than an open-market share purchase.
PROKIDNEY CORP. director William F. Doyle reported receiving a grant of stock options as part of non-employee director compensation. He was awarded 135,000 director stock options, each allowing him to buy one share of Class A Common Stock at an exercise price of $1.81 per share.
The options were granted at no upfront cost and will vest in full on the earlier of the one-year anniversary of the grant date or the company’s next annual general shareholder meeting. After this grant, Doyle holds 135,000 options directly, with an expiration date in 2036.
PROKIDNEY CORP. director Uma Sinha received a grant of options to buy 135,000 shares of Class A Common Stock at an exercise price of $1.81 per share. These director options were granted under the company’s non-employee director compensation policy and will vest in full on the earlier of one year from grant or the next annual general shareholder meeting.
PROKIDNEY CORP. director and 10% owner Pablo G. Legorreta received a grant of director stock options covering 135,000 shares of Class A Common Stock. The options have an exercise price of $1.81 per share and expire on May 28, 2036. They were granted under the company’s non-employee director compensation policy and will vest in full on the earlier of the one-year anniversary of the grant date or the company’s next annual general shareholder meeting.
PROKIDNEY CORP. director Brian JG Pereira received a grant of 135,000 director stock options as part of the company’s non-employee director compensation policy. The options have an exercise price of $1.81 per share, expire on May 28, 2036, and cover 135,000 shares of Class A common stock. According to the terms, the options will vest in full on the earlier of the one-year anniversary of the grant date or the company’s next annual general shareholder meeting, and this grant brings his reported option holdings in this award to 135,000 options.
PROKIDNEY CORP. major shareholder Control Empresarial de Capitales S.A. de C.V. converted its economic stake into a simpler structure. On the transaction date, it exchanged 63,118,645 Paired Interests (Class B Common Shares plus matching Common Units in ProKidney LLC) into 63,118,645 Class A Common Shares on a one-for-one basis at a stated price of $0.0000 per share, a non-cash conversion. Following this exchange, the holder reported owning 73,842,723 Class A Common Shares directly, with the corresponding Common Units and Class B Common Shares reduced to zero.
Coulston James reported acquisition or exercise transactions in this Form 4 filing.
PROKIDNEY CORP. reported that its Chief Financial Officer, James Coulston, received a grant of employee stock options covering 600,000 shares of the company’s stock. The options were awarded at no cost on the grant date and are scheduled to vest in substantially equal monthly installments over a four-year period beginning March 1, 2026, tying the CFO’s potential upside closely to the company’s long-term performance.
PROKIDNEY CORP. reported that Chief Regulatory Officer Darin J. Weber received a grant of 400,000 employee stock options with an exercise price of $0.00 per share. The options vest in substantially equal monthly installments over four years beginning on March 1, 2026.
Girolamo Todd C reported acquisition or exercise transactions in this Form 4 filing.
PROKIDNEY CORP. reported that Chief Legal Officer Todd C. Girolamo received a grant of employee stock options covering 600,000 shares on March 1, 2026. These options vest in substantially equal monthly installments over a four-year period beginning on March 1, 2026, meaning the award is earned gradually rather than all at once.
PROKIDNEY CORP. reported that Chief Executive Officer Bruce Culleton received a grant of employee stock options covering 3,000,000 shares of the company’s stock. These options were awarded as a derivative security with a reported price per share of $0.0000.
According to the filing, the option grant is scheduled to vest in substantially equal monthly installments over a four-year period beginning on March 1, 2026. This means the CEO’s right to exercise the options increases gradually each month over those four years.